ArticleJournal of assisted reproduction and genetics2025
An analysis of freeze-all cycles to investigate the association between elevated progesterone on day of trigger and oocyte quality.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate whether a premature rise in progesterone at the end of the follicular phase is adversely associated with oocyte quality in IVF cycles.
methodsA retrospective cohort study including patients less than or equal to 40 years of age undergoing their first IVF/ICSI cycle between January 2017 and December 2021 with freeze-all involving D5 or D6 blastocysts. Main Outcome Measure(s) Cumulative live birth rate (cLBR) and cumulative sustained implantation rate (cSIR).
result(s) A total of 1,373 IVF/ICSI cycles were included and categorized into progesterone tertiles (T1: 0.10-0.96 ng/ml; T2: 0.97-1.63 ng/ml; T3: 1.64-9.62 ng/ml). The cLBRs for T1, T2, and T3 were 54.0%, 56.6%, and 52.9%, respectively, and the cSIRs were 54.4%, 56.8%, and 53.3%, respectively. After adjustment for age, peak estradiol, and total dose of gonadotropins used, the risk of cLBR was statistically significantly increased for women in T2 (RR 1.19, 95% CI 1.06-1.33) and T3 (RR 1.14, 95% CI 1.01-1.28) compared with T1. Similar results were obtained for cSIR. For cycles with 5-10 oocytes, a statistically significant positive association was observed between T3 progesterone:oocyte ratio for both cLBR (RR 1.78, 95% CI 1.22-2.60) and cSIR (RR 1.80, 95% CI 1.24-2.62) compared with T1 after adjusting for oocyte number, while no such association was observed for cycles with >10 oocytes retrieved (cLBR: RR 0.95, 95% CI 0.84-0.95; cSIR: RR 0.95, 95% CI 0.83-1.08).
conclusionOur findings do not support an adverse association between a premature rise in progesterone and oocyte quality. In normal responders, this rise may be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.